Get the Stockscreener App
2.45
11.36%
0.25
After Hours:
2.55
0.10
+4.08%
Nexalin Technology Inc stock is traded at $2.45, with a volume of 104.01K.
It is up +11.36% in the last 24 hours and down -25.76% over the past month.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
See More
Previous Close:
$2.20
Open:
$2.32
24h Volume:
104.01K
Relative Volume:
0.30
Market Cap:
$32.59M
Revenue:
$128.60K
Net Income/Loss:
$-4.60M
P/E Ratio:
-3.8889
EPS:
-0.63
Net Cash Flow:
$-3.74M
1W Performance:
+8.89%
1M Performance:
-25.76%
6M Performance:
+249.75%
1Y Performance:
+487.53%
1-Day Range:
$2.2465
$2.49
1-Week Range:
$1.94
$2.49
52-Week Range:
$0.42
$4.4899
Nexalin Technology Inc Stock (NXL) Company Profile
Name
Nexalin Technology Inc
Sector
Industry
Phone
(832) 260-0222
Address
1776 YORKTOWN, HOUSTON
Compare NXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
2.45 | 32.59M | 128.60K | -4.60M | -3.74M | -0.63 |
|
ABT
Abbott Laboratories
|
127.42 | 220.99B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.73 | 148.66B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
378.05 | 144.26B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
91.87 | 117.97B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.90 | 41.68B | 5.72B | 4.17B | 259.90M | 6.97 |
Nexalin Technology Inc Stock (NXL) Latest News
Nexalin Technology, Inc. SEC 10-K Report - TradingView
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Corsicana Daily Sun
Nexalin Technology’s Senior VP Makes a Bold Stock Purchase - TipRanks
Nexalin technology’s Sr. VP Carolyn Shelton acquires $13,200 in stock - Investing.com India
Nexalin Technology Stock Price, Quotes and Forecasts | NASDAQ:NXL - Benzinga
Nexalin Technology, Inc. Receives USPTO Notice of Allowance for Patent on Innovative Treatment Method for Opioid and Substance Use Disorders - Nasdaq
Nexalin Technology Receives Notice of Allowance from the - GlobeNewswire
Could This Newly Patented Technology Transform How We Treat Addiction? - StockTitan
UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD - Yahoo Finance
Nexalin Technology Announces Initiation of Patient - GlobeNewswire
Nexalin Technology, Inc. Launches Clinical Trial for HALO™ Clarity Device to Treat Mild Traumatic Brain Injury and PTSD at UCSD - Nasdaq
Nexalin Technology announces initiation of patient recruitment in UCSD study - TipRanks
Can Nexalin's Brain Stimulation Technology Transform PTSD Treatment? UCSD Trial Now Recruiting Patients - StockTitan
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board - EIN News
Nexalin Technology Appoints General Wesley Clark to Military & Government Advisory Board - citybiz
Can NATO's Former Supreme Commander Help Nexalin Crack the Military Mental Health Market? - StockTitan
Nexalin Secures UCSD IRB Approval For Use Of HALO Clarity In PTSD And MTBI Clinical Studies - Nasdaq
Nexalin Technology Announces UCSD IRB Approval for use of - GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval For Use Of HALO Clarity In Clinical Trials For mTBI And PTSD Treatment - Marketscreener.com
Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval - Marketscreener.com
Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD - Nasdaq
Revolutionary Brain Treatment Device Enters Military PTSD Trials at UCSDPotential Breakthrough for Veterans - StockTitan
10,000 Shares in Nexalin Technology, Inc. (NASDAQ:NXL) Bought by Kingsview Wealth Management LLC - Defense World
Nexalin Technology Inc [NASDAQ: NXL] Sees Decrease in Stock Value - Knox Daily
Nexalin technology's chief medical officer buys $3,100 in shares - MSN
Nexalin Technology Inc’s latest rating changes from various analysts - Knox Daily
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition - GlobeNewswire
Nexalin Technology, Inc. Appointed Industry Co-Chair of National Traumatic Brain Injury Registry Coalition - Nasdaq
Nexalin (NXL) Secures Leadership Role in $4.5B Brain Injury MarketKey Details Investors Should See - StockTitan
Nexalin Technology announces effective registration statement - MSN
Nexalin Technology announces effective registration statement By Investing.com - Investing.com UK
Nexalin Technology Inc (NXL) Stock: A Year of Highs and Lows - The InvestChronicle
Nexalin Technology Inc (NXL) Becoming More Attractive for Investors - Knox Daily
Nexalin Technology announces publication of study of DIFS technology - MSN
Can you still get a good price for Nexalin Technology Inc (NXL) Shares at this point? - US Post News
Nexalin technology's chief medical officer buys $2,980 in common stock - MSN
Nexalin technology's chief medical officer buys $2,980 in common stock By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals launches Netherton awareness campaign - MSN
Nexalin’s Breakthrough DIFS™ Neurostimulation Device - GlobeNewswire
Nexalin Technology, Inc. Reports Landmark Study Highlights Efficacy of DIFS™ Technology in Reducing Blood Pressure in Patients with Major Depressive Disorder - Nasdaq
Clinical Trial: New Depression Therapy Achieves Dual Brain and Heart Benefits - StockTitan
Reviewing Nexeon Medsystems (OTCMKTS:NXNN) and Nexalin Technology (NASDAQ:NXL) - Defense World
NXLNexalin Technology, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin technology's chief medical officer buys $4,050 in stock - MSN
Nexalin Technology Inc Stock (NXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):